We evaluated the survival rates and medical expenditure in patients with lung cancer using a nationwide claims database in South Korea. A retrospective observational cohort study design was used, and 2,919 lung cancer patients and their matched controls were included. Medical expenditures were analyzed with the Kaplan-Meier sample average method, and patients were categorized into 4 groups by operation and primary treatment method (i.e. Patients with operation: OP = surgery, OP+CTx/RTx = surgery with anti-cancer drugs or radiotherapy; Patients without operation: CTx/RTx = anti-cancer drugs or radiotherapy, Supportive treatment). The 5-year medical expenditure per case was highest in the OP+CTx/RTx group ($36,013), followed by the CTx/RTx ($23,134), OP ($22,686), and supportive treatment group ($3,700). Lung cancer-related anti-cancer drug therapy was the major cost driver, with an average 53% share across all patients. Generalized linear regression revealed that monthly medical expenditure in lung cancer patients, after adjustment for follow-up month, was approximately 3.1–4.3 times higher than that in the control group (cost ratio for OP = 3.116, OP+CTx/RTx = 3.566, CTx/RTx = 4.340, supportive treatment = 4.157). The monthly medical expenditure at end of life was estimated at $2,139 for all decedents, and approximately a quarter of patients had received chemotherapy in the last 3 months. In conclusion, this study presented the quantified treatment costs of lung cancer on various aspects compared with matched controls according to the treatment of choice. In this study, patients with operation incurred lower lifetime treatment costs than patients with CTx/RTx or supportive treatment, indicating that the economic burden of lung cancer was affected by treatment method. Further studies including both cancer stage and treatment modality are needed to confirm these results and to provide more information on the economic burden according to disease severity.

Korea has the highest burden of tuberculosis (TB) among Organization for Economic Co-operation and Development countries. Various strategies have been implemented to eradicate TB in Korea, and it is critical to evaluate previous TB management outcomes before framing future TB policies. Over the past few decades, the rapid increase in the aging population in Korea has substantially impacted the incidence of TB among the elderly. Thus, in this study, we aimed to develop a mathematical model for the assessment of TB management outcomes incorporating special features of TB transmission dynamics in Korea. First, we incorporate 2-age groups in our TB model because TB epidemics in Korea are different between the elderly and the non-elderly (<65 years vs. ≥65 years). Second, because the public-private mix has had a full-fledged impact since 2012, this study was divided into two periods (2001–2011 and 2012–2018). We developed a mathematical model of TB transmission dynamics with 2-age groups and age-specific model parameters were estimated based on actual TB epidemic data from 2001 to 2018. These parameters included transmission rates, relapse rates, and recovery rates. We conducted sensitivity analyses of various parameters, and investigated the impacts of these parameters on TB incidence. Our results demonstrate that the overall outcomes of both age-groups improved in the period of 2012–2018 compared with that in the period of 2001–2011. Age-specific interventions should be implemented to reduce the overall TB incidence. More intensive treatment efforts should be focused on the elderly, while the early detection and treatment rates for latent TB were the most significant factor to reduce TB incidence in both groups.

Aim Most patients with Alzheimer's disease (AD) experience poor food intake and/or loss of appetite, which accelerates cognitive impairment. Several reports have shown that rivastigmine improves appetite in AD patients. The present study investigated the efficacy of a rivastigmine transdermal patch for the treatment of low food intake in AD patients. Methods AD patients, recruited through the Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study, were recognized as experiencing either a loss of appetite or poor food intake. A rivastigmine transdermal patch was administered to study participants for 16 weeks. Patients’ food intake, bodyweight, Mini‐Mental State Examination scores and any adverse events were recorded. Results A total of 38 patients with AD (age 86.2 ± 5.4 years) were examined. Their mean Mini‐Mental State Examination score was 10.1 ± 7.0 at baseline. A significant increase in food intake amount (54.9 ± 98.0 g, P < 0.01) and food intake ratio (9.3% ± 17.6%, P < 0.01) was observed by week 1, improvements that were maintained throughout the study duration. A multiple linear regression analysis showed that no independent variables were significantly associated with changes in food intake amount or ratio. Patients in the higher Mini‐Mental State Examination subgroup showed a trend change in food intake amount, although this did not reach statistical significance (P = 0.07). Conclusions The present study suggests that a rivastigmine transdermal patch might improve poor food intake or loss of appetite in patients with AD. Geriatr Gerontol Int 2019; ••: ••–••.

Sung Won Yoon, Hye Sung Han, Hae-Young Park, and Hyun Soon Sohn. Korean J Clin Pharm 2021;31:301-10. https://doi.org/10.24304/kjcp.2021.31.4.301